Zydus gets nod to conduct Phase II clinical study in patients with CAPS in Australia
CAPS is a rare life-long auto-inflammatory condition, and is classified under orphan diseases. CAPS patients also experience multiple neurological complications like sensorineural hearing loss, migraine, headache, aseptic meningitis and myalgia.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Australia Health | Biotechnology | Brain | Headache | Men | Meningitis | Migraine | Neurology | Pharmaceuticals | Study